Ips Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$3,864	1
2024	Research	$3,864	1
2022	Research	$14,128	7
2020	Research	$136,413	11
2019	Research	$254,906	12

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $193,820 4 payments
AstraZeneca AB $63,502 2 payments
Supernus Pharmaceuticals, Inc. $62,913 8 payments
AstraZeneca Pharmaceuticals LP $51,759 7 payments
Sage Therapeutics, Inc. $20,278 6 payments
ACADIA Pharmaceuticals Inc $15,783 1 payment
AbbVie, Inc. $3,622 3 payments
Mylan Specialty L.P. $1,500 1 payment

Studies the money was for Research payments · program years 2019–2025

A Multicenter Randomized Non Interventional Parallel Design 4 Week Duration Study in Adults to Evaluate the Number and Frequency of Out of Office Blood Pressure Self Measurements to Accurately Diagnose the Presence Or Absence of Hypertension $168,184 2 payments
An Open-Label, Multi-Center, Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of 2-Week Treatment with Inhaled AZD7594 in Adolescents 12 to 17 years with Asthma (AMBER) $63,502 2 payments
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $33,524 1 payment
A 5 Year Prospective Study of An Anti Amyloid Therapy Cad106 Or Cnp520 in Slowing and Or Postponing Cognitive Decline in Asymptomatic Apoe 4 Homozygotes at Risk for Developing Alzheimers Disease Dementia $25,636 2 payments
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficithyperactivity Disorder Adhd $25,342 3 payments
Evaluation of Spn-812 Er 200 and 400 MG Efficacy and Safety in Children With Adhd - A Double-Blind, Placebo-Controlled, Pivotal Trial $23,808 3 payments
Acp-103-042 $15,783 1 payment
Evaluation of Spn-812 Er 400 and 600 MG Efficacy and Safety in Adolescents With Adhd - A Double-Blind, Placebo- Controlled, Pivotal Trial $13,763 2 payments
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma $10,084 2 payments
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Sage-217 in the Treatment of Adult Subjects With Major Depressive Disorder $9,461 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.